PARK8 Antibody

Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson's disease identified to date. LRRK2, a genetic mutation, was recently found linked to about 5 percent of inherited cases of Parkinson's disease. By high-resolution recombination mapping and candidate gene sequencing in 46 families, 6 disease-segregating mutations (5 missense and 1 putative splice site mutation). It may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism. LRRK2 belongs to the ROCO protein family and includes a protein kinase domain of the MAPKKK class and several other major functional domains.

Target	PARK8
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Tested Applications	IHC
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Immunogen	Human PARK8.
Purification	Purified Rabbit Polyclonal Antibody.
Isotype	IgG
Conjugation	Unconjugated
Specificity	This PARK8 (LRRK2) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 931-962 amino acids from human PARK8 (LRRK2).
Storage	Aliquot and store at -20 °C. Avoid repeated freeze/thaw cycles.
Swiss Prot	Q5S007
NCBI Accession	NP_940980.3
Buffer	PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
Availability	Shipped within 5-10 working days.
Note	This product is for research use only.